NCT06006013 2026-02-18Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerEmory UniversityPhase 2 Recruiting21 enrolled